U.S. markets open in 2 hours 32 minutes

Boston Scientific Corporation (BSX)

NYSE - NYSE Precio retrasado. Divisa en USD.
Añadir a la lista de seguimiento
68.62+0.68 (+1.00%)
Al cierre: 04:00PM EDT
68.70 +0.08 (+0.12%)
Antes de la apertura del mercado: 06:11AM EDT

Boston Scientific Corporation

300 Boston Scientific Way
Marlborough, MA 01752-1234
United States
508 683 4000
https://www.bostonscientific.com

Sector(es)Healthcare
IndustriaMedical Devices
Empleados a tiempo completo48,000

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Michael F. MahoneyChairman, President & CEO4.83M12.98M1965
Mr. Daniel J. BrennanExecutive VP & CFO2.15M1.71M1966
Mr. Joseph M. FitzgeraldExecutive VP & Group President of Cardiology1.84M4.7M1964
Mr. Jeffrey B. MirvissExecutive VP & President of Peripheral Interventions1.44MN/D1966
Mr. Arthur Crosswell ButcherExecutive VP and Group President of MedSurg & Asia Pacific1.49M626.04k1971
Mr. David J. RouxIndependent Director135kN/D1957
Mr. John Bradley SorensonExecutive Vice President of Global OperationsN/DN/D1968
Ms. Emily WoodworthSenior VP, Global Controller & Chief Accounting OfficerN/DN/D1978
Ms. Jodi Euerle EddySenior VP and Chief Information & Digital OfficerN/DN/D1974
Mr. Jonathan R MonsonSenior VP of Investor RelationsN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Gestión corporativa

La calificación ISS Governance QuickScore de Boston Scientific Corporation a partir del 1 de marzo de 2024 es 9. Las puntuaciones principales son Auditoría: 10; Junta: 9; Derechos del accionista: 8; Compensación: 7.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.